JP7170662B2 - Ｖｍａｔ２インヒビター化合物およびその組成物 - Google Patents

Ｖｍａｔ２インヒビター化合物およびその組成物 Download PDF

Info

Publication number
JP7170662B2
JP7170662B2 JP2019556587A JP2019556587A JP7170662B2 JP 7170662 B2 JP7170662 B2 JP 7170662B2 JP 2019556587 A JP2019556587 A JP 2019556587A JP 2019556587 A JP2019556587 A JP 2019556587A JP 7170662 B2 JP7170662 B2 JP 7170662B2
Authority
JP
Japan
Prior art keywords
methyl
piperazino
methoxy
pharmaceutically acceptable
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517607A5 (enExample
JP2020517607A (ja
Inventor
ニコル ハリオット，
ドナルド ヘッティンガー，
ショーン ブラナム，
ジェフリー シー． カルヘーン，
Original Assignee
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7170662(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューロクライン バイオサイエンシーズ，インコーポレイテッド filed Critical ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Publication of JP2020517607A publication Critical patent/JP2020517607A/ja
Publication of JP2020517607A5 publication Critical patent/JP2020517607A5/ja
Application granted granted Critical
Publication of JP7170662B2 publication Critical patent/JP7170662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019556587A 2017-04-19 2018-04-17 Ｖｍａｔ２インヒビター化合物およびその組成物 Active JP7170662B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US62/487,413 2017-04-19
US201862652837P 2018-04-04 2018-04-04
US62/652,837 2018-04-04
PCT/US2018/028031 WO2018195121A1 (en) 2017-04-19 2018-04-17 Vmat2 inhibitor compounds and compositions thereof

Publications (3)

Publication Number Publication Date
JP2020517607A JP2020517607A (ja) 2020-06-18
JP2020517607A5 JP2020517607A5 (enExample) 2021-05-27
JP7170662B2 true JP7170662B2 (ja) 2022-11-14

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556587A Active JP7170662B2 (ja) 2017-04-19 2018-04-17 Ｖｍａｔ２インヒビター化合物およびその組成物

Country Status (17)

Country Link
US (1) US11040970B2 (enExample)
EP (1) EP3612532B1 (enExample)
JP (1) JP7170662B2 (enExample)
KR (1) KR20190140968A (enExample)
CN (1) CN110770236B (enExample)
AU (1) AU2018254429A1 (enExample)
BR (1) BR112019021853A2 (enExample)
CA (1) CA3060251A1 (enExample)
CL (1) CL2019002919A1 (enExample)
CO (1) CO2019011604A2 (enExample)
ES (1) ES2971230T3 (enExample)
JO (1) JOP20190239A1 (enExample)
MA (1) MA50145A (enExample)
MX (1) MX2019012336A (enExample)
PE (1) PE20191784A1 (enExample)
TW (1) TW201841913A (enExample)
WO (1) WO2018195121A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170136A (ko) 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
JOP20200298A1 (ar) * 2018-06-14 2020-11-22 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020086765A1 (en) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
CA3229341A1 (en) 2021-08-20 2023-02-23 Ryan TERRY-LORENZO Methods of screening for vmat2 inhibitors
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509925A (ja) 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
WO2009126305A1 (en) 2008-04-11 2009-10-15 The Trustees Of Columbia University Glucose metabolism modulating compounds
JP2010509366A (ja) 2006-11-08 2010-03-25 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984A (zh) 2010-11-25 2011-12-21 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
ATE437876T1 (de) 2003-06-20 2009-08-15 Hoffmann La Roche Hexahydropyridoisochinoline als dpp-iv- inhibitoren
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2014043866A1 (zh) 2012-09-19 2014-03-27 中国科学院福建物质结构研究所 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
KR102586138B1 (ko) 2015-02-06 2023-10-05 뉴로크린 바이오사이언시즈 인코퍼레이티드 [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509925A (ja) 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
JP2010509366A (ja) 2006-11-08 2010-03-25 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 置換３−イソブチル−９，１０−ジメトキシ−１，３，４，６，７，１１ｂ−ヘキサヒドロ−２Ｈ−ピリド［２，１−ａ］イソキノリン−２−オール化合物およびそれに関連する方法
WO2009126305A1 (en) 2008-04-11 2009-10-15 The Trustees Of Columbia University Glucose metabolism modulating compounds
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984A (zh) 2010-11-25 2011-12-21 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Gilbert, J. et al.，Nitrogen analogs of emetine: synthesis and evaluation of the antiamebic and antitumor activity of 3-azaemetine, and attempted synthesis of 2-azaemetine，Farmaco, Edizione Scientifica，1978年，33(4)，pp. 237-252
Koelzer, M. et al.，Synthesis of Bioactive 2-Aza-Analogues of Ipecac and Alangium Alkaloids，ChemMedChem，2010年，5(9)，pp. 1456-1464
Reginato, G. et al.，Stereoselective Synthesis of 3-Substituted Tetrahydropyrazinoisoquinolines via Intramolecular Cyclization of Enantiomerically Enriched Dihydro-2H-pyrazines，Organic Letters，2015年，17(3)，pp. 398-401

Also Published As

Publication number Publication date
US11040970B2 (en) 2021-06-22
CN110770236B (zh) 2023-03-24
MX2019012336A (es) 2020-07-14
PE20191784A1 (es) 2019-12-24
KR20190140968A (ko) 2019-12-20
AU2018254429A1 (en) 2019-11-07
EP3612532B1 (en) 2023-12-13
EP3612532A1 (en) 2020-02-26
MA50145A (fr) 2020-07-29
CL2019002919A1 (es) 2020-01-17
EP3612532C0 (en) 2023-12-13
WO2018195121A1 (en) 2018-10-25
BR112019021853A2 (pt) 2020-05-26
TW201841913A (zh) 2018-12-01
CO2019011604A2 (es) 2019-10-31
CN110770236A (zh) 2020-02-07
CA3060251A1 (en) 2018-10-25
JP2020517607A (ja) 2020-06-18
JOP20190239A1 (ar) 2019-10-09
US20200131173A1 (en) 2020-04-30
ES2971230T3 (es) 2024-06-04

Similar Documents

Publication Publication Date Title
EP3612532B1 (en) Vmat2 inhibitor compounds and compositions thereof
JP7155206B2 (ja) 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
JP7107950B2 (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024114905A (ja) Ｖｍａｔ２インヒビター化合物、上記化合物に関する組成物および方法
TW202515564A (zh) 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
HK40049687A (en) Vmat2 inhibitor compounds, compositions, and methods relating thereto
HK1248116B (en) Vmat2 inhibitors for treating neurological diseases or disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221101

R150 Certificate of patent or registration of utility model

Ref document number: 7170662

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350